NSP COVID-19 vaccine / Predictive Oncology, National Institutes of Health - LARVOL DELTA

Predictive Oncology and Dr. Daniel Carter Collaborating to Develop a Potential COVID-19 Vaccine Utilizing Novel Nanoparticle Vaccine Platform, Based on NSP-10 (GlobeNewswire, Predictive Oncology Inc.) - "Predictive Oncology...entered the race to develop a COVID-19 vaccine. The groundbreaking vaccine technology being developed by Dr. Carter is based on a self-assembling nanoparticle called NSP-10 (NSP is Non Specific Protein)....POAI has entered into an agreement with Dr. Carter under which POAI is licensing this technology, subject to certain conditions including additional documentation....The NSP COVID-19 vaccine has produced atypically strong titers against the coronavirus spike protein in small animals using a single small dose of plasmid-based DNA....Vaccine in support of a Phase I clinical trial is in production with expected delivery later this month. Predictive Oncology’s next step, in support of its partnership with Dr. Carter, is seeking quotes for a Phase 1 clinical trial..."

Licensing / partnership • Infectious Disease • Novel Coronavirus Disease